212
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      MHC Class I Cross-Presentation by Dendritic Cells Counteracts Viral Immune Evasion

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          DCs very potently activate CD8 + T cells specific for viral peptides bound to MHC class I molecules. However, many viruses have evolved immune evasion mechanisms, which inactivate infected DCs and might reduce priming of T cells. Then MHC class I cross-presentation of exogenous viral Ag by non-infected DCs may become crucial to assure CD8 + T cell responses. Although many vital functions of infected DCs are inhibited in vitro by many different viruses, the contributions of cross-presentation to T cell immunity when confronted with viral immune inactivation in vivo has not been demonstrated up to now, and remains controversial. Here we show that priming of Herpes Simplex Virus (HSV)-, but not murine cytomegalovirus (mCMV)-specific CD8 + T cells was severely reduced in mice with a DC-specific cross-presentation deficiency. In contrast, while CD8 + T cell responses to mutant HSV, which lacks crucial inhibitory genes, also depended on CD8α + DCs, they were independent of cross-presentation. Therefore HSV-specific CTL-responses entirely depend on the CD8α + DC subset, which present via direct or cross-presentation mechanisms depending on the immune evasion equipment of virus. Our data establish the contribution of cross-presentation to counteract viral immune evasion mechanisms in some, but not all viruses.

          Related collections

          Most cited references53

          • Record: found
          • Abstract: found
          • Article: not found

          Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity.

          Although in vitro observations suggest that cross-presentation of antigens is mediated primarily by CD8alpha+ dendritic cells, in vivo analysis has been hampered by the lack of systems that selectively eliminate this cell lineage. We show that deletion of the transcription factor Batf3 ablated development of CD8alpha+ dendritic cells, allowing us to examine their role in immunity in vivo. Dendritic cells from Batf3-/- mice were defective in cross-presentation, and Batf3-/- mice lacked virus-specific CD8+ T cell responses to West Nile virus. Importantly, rejection of highly immunogenic syngeneic tumors was impaired in Batf3-/- mice. These results suggest an important role for CD8alpha+ dendritic cells and cross-presentation in responses to viruses and in tumor rejection.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Cd8+ but Not Cd8− Dendritic Cells Cross-Prime Cytotoxic T Cells in Vivo

            Bone marrow–derived antigen-presenting cells (APCs) take up cell-associated antigens and present them in the context of major histocompatibility complex (MHC) class I molecules to CD8+ T cells in a process referred to as cross-priming. Cross-priming is essential for the induction of CD8+ T cell responses directed towards antigens not expressed in professional APCs. Although in vitro experiments have shown that dendritic cells (DCs) and macrophages are capable of presenting exogenous antigens in association with MHC class I, the cross-presenting cell in vivo has not been identified. We have isolated splenic DCs after in vivo priming with ovalbumin-loaded β2-microglobulin–deficient splenocytes and show that they indeed present cell-associated antigens in the context of MHC class I molecules. This process is transporter associated with antigen presentation (TAP) dependent, suggesting an endosome to cytosol transport. To determine whether a specific subset of splenic DCs is involved in this cross-presentation, we negatively and positively selected for CD8− and CD8+ DCs. Only the CD8+, and not the CD8−, DC subset demonstrates cross-priming ability. FACS® studies after injection of splenocytes loaded with fluorescent beads showed that 1 and 0.6% of the CD8+ and the CD8− DC subsets, respectively, had one or more associated beads. These results indicate that CD8+ DCs play an important role in the generation of cytotoxic T lymphocyte responses specific for cell-associated antigens.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The CD8+ dendritic cell subset.

              Mouse lymphoid tissues contain a subset of dendritic cells (DCs) expressing CD8 alpha together with a pattern of other surface molecules that distinguishes them from other DCs. These molecules include particular Toll-like receptor and C-type lectin pattern recognition receptors. A similar DC subset, although lacking CD8 expression, exists in humans. The mouse CD8(+) DCs are non-migrating resident DCs derived from a precursor, distinct from monocytes, that continuously seeds the lymphoid organs from bone marrow. They differ in several key functions from their CD8(-) DC neighbors. They efficiently cross-present exogenous cell-bound and soluble antigens on major histocompatibility complex class I. On activation, they are major producers of interleukin-12 and stimulate inflammatory responses. In steady state, they have immune regulatory properties and help maintain tolerance to self-tissues. During infection with intracellular pathogens, they become major presenters of pathogen antigens, promoting CD8(+) T-cell responses to the invading pathogens. Targeting vaccine antigens to the CD8(+) DCs has proved an effective way to induce cytotoxic T lymphocytes and antibody responses.
                Bookmark

                Author and article information

                Journal
                Front Immunol
                Front Immunol
                Front. Immun.
                Frontiers in Immunology
                Frontiers Media S.A.
                1664-3224
                31 October 2012
                26 November 2012
                2012
                : 3
                : 348
                Affiliations
                [1] 1Institute for Immunology, Ludwig-Maximilians-University Munich Munich, Germany
                [2] 2Department of Pathology and Immunology, Howard Hughes Medical Institute, Washington University School of Medicine St. Louis, MO, USA
                [3] 3Department of Life Science and Biotechnology, University of Ferrara Ferrara, Italy
                [4] 4Max von Pettenkofer-Institut, Ludwig-Maximilians-University Munich Munich, Germany
                Author notes

                Edited by: Peter M. Van Endert, Université Paris Descartes/INSERM, France

                Reviewed by: Sven Burgdorf, Rheinische Friedrich-Wilhelms-Universität, Germany; Marianne Boes, University Medical Centre Utrecht, Netherlands

                *Correspondence: Thomas Brocker, Institute for Immunology, Ludwig-Maximilians- University Munich, Goethestraße 31, 80336 München, Germany. e-mail: tbrocker@ 123456med.uni-muenchen.de

                Present address: Alejandro A. Castello, Universidad Nacional de Quilmes, Buenos Aires, Argentina.

                Katrin Nopora and Caroline A. Bernhard contributed equally to this paper and share the first authorship.

                This article was submitted to Frontiers in Antigen Presenting Cell Biology, a specialty of Frontiers in Immunology.

                Article
                10.3389/fimmu.2012.00348
                3505839
                23189079
                e09b1321-eb82-422c-81f6-f3d5efd51d2b
                Copyright © 2012 Nopora, Bernhard, Ried, Castello, Murphy, Marconi, Koszinowski and Brocker.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.

                History
                : 24 October 2012
                : 05 November 2012
                Page count
                Figures: 4, Tables: 0, Equations: 0, References: 61, Pages: 10, Words: 7268
                Categories
                Immunology
                Original Research

                Immunology
                cross-priming,dendritic cells,immune evasion
                Immunology
                cross-priming, dendritic cells, immune evasion

                Comments

                Comment on this article